Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines : World Health Organization consultations, October 2021—March 2022

Q3

Autores:

Prudden, Holly J.
Achilles, Sharon L.
Schocken, Celina
Broutet, Nathalie
Canfell, Karen
Akaba, Hiroki
Basu, Partha
Bhatla, Neerja
Chirenje, Z. Mike
Delany-Moretlwe, Sinead
Denny, Lynette
Gamage, Deepa G.
Herrero, Rolando
Hutubessy, Raymond
Villa, Luisa Lina
Murillo, Raul
Schiller, John T.
Stanley, Margaret
Temmerman, Marleen
Zhao, Fanghui
Ogilvie, Gina
Kaslow, David C.
Dull, Peter
Gottlieb, Sami L.
Therapeutic HPV Vaccine PPC Expert Consultation Group

Tipo de recurso:

Article of journal

Fecha de publicación:

2022

Institución:

Pontificia Universidad Javeriana

Repositorio:

Repositorio Universidad Javeriana

Idioma:

eng

OAI Identifier:

oai:repository.javeriana.edu.co:10554/63858

Acceso en línea:

https://www.sciencedirect.com/science/article/pii/S0264410X22009999?via%3Dihub
http://hdl.handle.net/10554/63858
https://doi.org/10.1016/j.vaccine.2022.08.020

Palabra clave:

Cervical cancer
HPV
Therapeutic HPV vaccine
Preferred product characteristics

Rights

License

Atribución-NoComercial 4.0 Internacional